National Institute for Health and Clinical Excellence decisions may be subject to greater scrutiny following yesterday's Court of Appeal ruling over Alzheimer's drugs.

Welcoming the ruling that NICE must provide open access to the calculations that decide a medicine's cost-effectiveness, the Association of the British Pharmaceutical Industry said this would ensure the right medicines reached the right patients.